S&P 500   3,204.45 (-0.69%)
DOW   26,742.86 (-0.47%)
QQQ   256.55 (-1.67%)
AAPL   384.99 (-1.51%)
MSFT   203.57 (-2.15%)
FB   238.54 (-0.72%)
GOOGL   1,499.87 (-1.12%)
AMZN   2,956.00 (-1.76%)
NVDA   399.91 (-2.24%)
CGC   17.90 (-1.38%)
BABA   242.46 (-2.71%)
MU   49.84 (-1.33%)
GE   7.16 (+0.28%)
TSLA   1,484.06 (-4.01%)
AMD   54.19 (-2.08%)
T   30.38 (+1.23%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   75.77 (-1.16%)
DIS   119.11 (-1.48%)
NFLX   514.57 (-1.66%)
BAC   24.00 (-2.44%)
BA   180.77 (-3.82%)
S&P 500   3,204.45 (-0.69%)
DOW   26,742.86 (-0.47%)
QQQ   256.55 (-1.67%)
AAPL   384.99 (-1.51%)
MSFT   203.57 (-2.15%)
FB   238.54 (-0.72%)
GOOGL   1,499.87 (-1.12%)
AMZN   2,956.00 (-1.76%)
NVDA   399.91 (-2.24%)
CGC   17.90 (-1.38%)
BABA   242.46 (-2.71%)
MU   49.84 (-1.33%)
GE   7.16 (+0.28%)
TSLA   1,484.06 (-4.01%)
AMD   54.19 (-2.08%)
T   30.38 (+1.23%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   75.77 (-1.16%)
DIS   119.11 (-1.48%)
NFLX   514.57 (-1.66%)
BAC   24.00 (-2.44%)
BA   180.77 (-3.82%)
S&P 500   3,204.45 (-0.69%)
DOW   26,742.86 (-0.47%)
QQQ   256.55 (-1.67%)
AAPL   384.99 (-1.51%)
MSFT   203.57 (-2.15%)
FB   238.54 (-0.72%)
GOOGL   1,499.87 (-1.12%)
AMZN   2,956.00 (-1.76%)
NVDA   399.91 (-2.24%)
CGC   17.90 (-1.38%)
BABA   242.46 (-2.71%)
MU   49.84 (-1.33%)
GE   7.16 (+0.28%)
TSLA   1,484.06 (-4.01%)
AMD   54.19 (-2.08%)
T   30.38 (+1.23%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   75.77 (-1.16%)
DIS   119.11 (-1.48%)
NFLX   514.57 (-1.66%)
BAC   24.00 (-2.44%)
BA   180.77 (-3.82%)
S&P 500   3,204.45 (-0.69%)
DOW   26,742.86 (-0.47%)
QQQ   256.55 (-1.67%)
AAPL   384.99 (-1.51%)
MSFT   203.57 (-2.15%)
FB   238.54 (-0.72%)
GOOGL   1,499.87 (-1.12%)
AMZN   2,956.00 (-1.76%)
NVDA   399.91 (-2.24%)
CGC   17.90 (-1.38%)
BABA   242.46 (-2.71%)
MU   49.84 (-1.33%)
GE   7.16 (+0.28%)
TSLA   1,484.06 (-4.01%)
AMD   54.19 (-2.08%)
T   30.38 (+1.23%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   75.77 (-1.16%)
DIS   119.11 (-1.48%)
NFLX   514.57 (-1.66%)
BAC   24.00 (-2.44%)
BA   180.77 (-3.82%)
Log in

NYSEAMERICAN:NBYNovaBay Pharmaceuticals Stock Price, Forecast & News

$1.37
+0.08 (+6.20 %)
(As of 07/16/2020 11:52 AM ET)
Add
Compare
Today's Range
$1.25
Now: $1.37
$1.44
50-Day Range N/A
52-Week Range
$0.24
Now: $1.37
$1.94
Volume53,897 shs
Average Volume3.88 million shs
Market Capitalization$39.47 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Read More
NovaBay Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.84 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NBY
CUSIPN/A
Phone+1-510-8998800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees70
Market Cap$39.47 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of NovaBay Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NovaBay Pharmaceuticals.

When is NovaBay Pharmaceuticals' next earnings date?

NovaBay Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for NovaBay Pharmaceuticals.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.01. The biopharmaceutical company earned $1.89 million during the quarter. View NovaBay Pharmaceuticals' earnings history.

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals's stock reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for NBY?

1 analysts have issued twelve-month target prices for NovaBay Pharmaceuticals' shares. Their forecasts range from $1.10 to $1.10. On average, they expect NovaBay Pharmaceuticals' share price to reach $1.10 in the next year. This suggests that the stock has a possible downside of 19.7%. View analysts' price targets for NovaBay Pharmaceuticals.

Has NovaBay Pharmaceuticals been receiving favorable news coverage?

News stories about NBY stock have trended positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. NovaBay Pharmaceuticals earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news about NovaBay Pharmaceuticals.

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 249,000 shares, an increase of 49.4% from the June 15th total of 166,700 shares. Based on an average trading volume of 4,260,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.3% of the company's stock are sold short. View NovaBay Pharmaceuticals' Current Options Chain.

Who are some of NovaBay Pharmaceuticals' key competitors?

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Gilead Sciences (GILD), Novavax (NVAX), Inovio Pharmaceuticals (INO), Opko Health (OPK), Biocept (BIOC), Advanced Micro Devices (AMD), CorMedix (CRMD), Exelixis (EXEL), NVIDIA (NVDA) and Arbutus Biopharma (ABUS).

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the following people:
  • Mr. Justin M. Hall, Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. Jason Philip Raleigh, Interim CFO, Treasurer & Corp. Controller (Age 42)
  • Dr. David W. Stroman, Sr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory Board (Age 74)

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $1.37.

How big of a company is NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals has a market capitalization of $39.47 million. NovaBay Pharmaceuticals employs 70 workers across the globe.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is novabay.com.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.